EyeCool Therapeutics Set to Present Key Findings on ETX-4143 Addressing Chronic Ocular Surface Pain

In a significant development for ophthalmology, EyeCool Therapeutics is set to unveil novel data regarding its investigational device, ETX-4143, at the Association for Research in Vision and Ophthalmology meeting in Denver, highlighting a promising approach to treating chronic ocular surface pain. This debilitating condition, which currently lacks any FDA-approved treatments, has long represented a major unmet medical need. The new data, compiled from a one-year follow-up involving nineteen treated subjects, suggests that ETX-4143 can provide meaningful relief by gently cooling the eye surface to target pain-signaling nerves. Key findings presented include the maintenance of improved visual acuity and significant pain reduction, with 60% of participants reporting mean pain scores remaining below their initial baseline. Furthermore, the study indicated a remarkable improvement in corneal nerve sensitivity, with these levels normalizing and sustaining even one year after treatment—a point highlighted by experts as crucial for patients with underlying nerve abnormalities. The clinical data also pointed toward potential immune benefits, suggesting that the treatment may modulate the activity of immune cells on the ocular surface, while rigorous safety evaluations found no adverse effects. These results reinforce the company’s case for ETX-4143 as a potential non-pharmacological alternative, marking a major milestone in the fight against chronic eye discomfort. Learn more: https://eyecooltx.com

See All Episodes